Pfizer’s Tukysa approved for front-line breast cancer (PFE)

Pfizer's Tukysa gained FDA approval for expanded use in HER2-positive breast cancer maintenance treatment. The drug contributed 0.9% to Pfizer's Q2 revenue, with U.S. sales declining 11%. Shares rose 2.04% on October 7. The approval does not provide immediate earnings forecasts, and Q3 sales will not reflect the new indication.

The FDA approved Pfizer's (NYSE:PFE) TUKYSA for HER2-positive breast cancer maintenance therapy. Clinical trials showed a 35.9% reduction in disease progression risk. Shares rose 1.83% to $28.00 on the news. Technical analysis suggests potential for further gains.

The FDA approved Pfizer's tucatinib (Tukysa) in combination with trastuzumab and pertuzumab for maintenance treatment of HER2-positive metastatic breast cancer. The approval is based on the HER2CLIMB-05 trial, which showed an 8.6-month improvement in median progression-free survival compared to placebo. According to Pfizer, this approval expands tucatinib's use to the frontline setting, offering a chemotherapy-free option.

Pfizer (PFE) received FDA approval for Tukysa as a maintenance treatment for HER2-positive breast cancer, following positive trial results. The company reports a 6.11% dividend yield, a 0.71 payout ratio, and a GF Score of 74. Insider buying and mixed guru activity were noted. PFE's stock is currently 6.3% overvalued relative to its GF Value of $26.42.

Pfizer announced that the FDA approved its Tukysa combination therapy for maintenance treatment of metastatic breast cancer. The approval is a significant milestone for the company's oncology portfolio. Pfizer's stock has seen a 12.93% increase year-to-date.

Pfizer announced FDA approval for Tukysa as a front-line maintenance treatment for a form of breast cancer, expanding its use to an earlier stage. The approval follows a Phase 3 trial showing a 36% reduction in disease progression or death risk. Pfizer noted increased hepatotoxicity severity as a side effect.